Merck Proposes 27,000-Patient Observational Trial As Follow-up for Male Use of Gardasil
This article was originally published in The Pink Sheet Daily
Extension of vaccine to 9-15 year-old boys to prevent genital warts receives lopsided FDA advisory committee votes but some questions about postmarketing studies and duration of effect.
You may also be interested in...
Company unveils data at European conference supporting use in women ages 27 through 45; data was sent to FDA late last year.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.